Cassava Sciences (SAVA) Announces New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
Cassava Sciences, Inc. (Nasdaq: NASDAQ:), a clinical-stage biotechnology company, today announced new data…
- In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior disclosures. - No government agency has informed…
Breadcrumb Trail Links PMN Business Author of the article: Reuters Marisa Taylor and Mike Spector Article content WASHINGTON — The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc…
Pune, India, June 22, 2022 (GLOBE NEWSWIRE) -- According to the report published by Fortune Business Insights in a report, titled “Cassava Starch Market Size, Share & Industry Analysis, By Type (Native Starch, Modified Starch, and…
New website (www.Rethink-ALZ.com) is intended to increase visibility and information for potential study participants.Rethink-ALZ.com connects patients with nearest participating clinical site.Phase 3 efficacy studies now in over 25…
AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present at H.C. Wainwright’s 23rd Annual…
AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau analysis from a previously disclosed…
AUSTIN, Texas, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today that it has reached agreement with the U.S. Food and Drug Administration…